Skip to main content
TipRanks
Go Ultimate75% OFF

PTC Therapeutics (P91) AI Stock Analysis

1 Followers
CH:P91

PTC Therapeutics

(BX Swiss:P91)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Sephience Commercial TractionSephience is demonstrating meaningful early adoption across U.S. and international markets, supported by sequential revenue growth and a rising active-patient base. Continued penetration of therapy-naive patients, Kuvan switchers and underserved PKU populations could provide a durable commercial growth platform.
Negative Factors
Uneven Profitability and Cash FlowRecent cash generation has not yet proven durable because strong 2025 results were followed by only slightly positive operating cash flow and negative free cash flow on a TTM basis. Continued volatility could limit funding flexibility and make the profitability recovery harder to sustain.

PTC Therapeutics Business Overview & Revenue Model

Company Description

PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized...

PTC Therapeutics Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|Next Earnings Date:Feb 23, 2027
Earnings Call SentimentPositive

The call was strongly positive, driven by record product revenue, a more than 100% year-over-year increase in product revenue, raised 2026 guidance, strong Sephience launch momentum, a large remaining PKU opportunity, progress across the pipeline and a strengthened cash position. The main challenges were generic pressure on Emflaza, the lack of expected repeat government orders for Translarna in the fourth quarter, pending international reimbursement decisions, cumulative Sephience discontinuations in the low 20% range and the delayed votoplam FDA meeting. Highlights significantly outweighed lowlights.

Positive Updates

Record Revenue and Raised 2026 Guidance
Third-quarter total revenue was $358 million, including $276 million of product revenue, which increased over 100% from $131 million in the third quarter of 2025. The company raised full-year 2026 product revenue guidance to $960 million to $990 million and total revenue guidance to $1.29 billion to $1.32 billion, representing 64% to 69% year-over-year product revenue growth. Management expects to achieve cash flow breakeven in 2026.

Negative Updates

Emflaza Facing Increased Generic Pricing Pressure
Management stated that a new generic entrant in the fourth quarter has brought Emflaza pricing down significantly and has impacted expectations for the product.

Company Guidance

PTC Therapeutics raised full year 2026 product revenue guidance to $960 million to $990 million and now expects total revenue of $1.29 billion to $1.32 billion, representing 64% to 69% year-over-year product revenue growth, and expects to achieve cash flow breakeven in 2026; international revenue is expected to continue to grow with acceleration points as access and reimbursement are achieved in additional countries over the course of 2027, ST-920’s rolling BLA submission is expected to be completed in Q4 2026 with the potential for approval and commercial launch in 2027, the votoplam Type C meeting is now planned for the first quarter of 2027 and INVEST-HD is planned to enroll approximately 770 early symptomatic patients, PROVE-FA is expected to enroll approximately 120 individuals between 7 and 21 years of age, pricing and reimbursement in France, Italy and Spain are anticipated to be finalized somewhere in the first half of 2027, PTC303 is on schedule to enter the clinic in 2027, and the company believes ST-920 could be accretive in 2027 and remains confident in the $2 billion-plus peak sales opportunity for Sephience.

PTC Therapeutics Risk Analysis

PTC Therapeutics disclosed 53 risk factors in its most recent earnings report. PTC Therapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

PTC Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CH:P91 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SRPTSRPT58Neutral$1.62B168.581.04%―-18.95%59.85%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
RARERARE48Neutral$1.62B-3.08213.22%―15.76%12.63%
STOKSTOK46Neutral$1.74B-7.01-67.30%―-86.28%-634.38%
DYNDYN44Neutral$3.13B-4.59-69.73%――0.69%
IONSIONS42Neutral$4.66B-8.66-120.44%―-0.79%-106.48%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%IONSSRPTRARESTOKDYNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CH:P91 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IONSIonis Pharmaceuticals Inc.26.96-47.04-63.57%
SRPTSarepta Therapeutics Inc.14.77-1.62-9.88%
RAREUltragenyx Pharmaceutical, Inc.16.70-15.16-47.58%
STOKStoke Therapeutics26.41-2.07-7.27%
DYNDyne Therapeutics, Inc.16.02-4.58-22.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.